RECHERCHEThis trial was co-financed with the Children without Cancer race of 2013 BEACON – a randomized phase IIb trial of BEyACizumab added to temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma – enables to search for new treatments on high risk neuroblastoma: 1 new medicine + chemotherapy (functional imaging). BEACON will become the global strategy to treat children with relapsed Neuroblastoma in Europe. The functional imaging network will enable a better analysis of BEACON results and a unique international infrastructure for other ITCC projects.   Promotor: University of Birmingham, United Kingdom Main investigator: Dr Lucas Moreno French investigator: Hospital of Toulouse, Dr Marion Gambart First patient in the study: July 2013 Planned enrollment: 160 patients – 97 patients enrolled by the end of 2016 Number of centers opened: 32 centers opened Global trial duration: recruitment until end of 2018, closed in July 2022 Concerned countries: England, France, Ireland, Spain, Italy, the Netherlands, Denmark, Austria and Switzerland Co-financing by Imagine for Margo: €250,000 for the trial and €123,250 for functional imaging   What is the situation today?

X En poursuivant votre navigation sur ce site, vous acceptez l’utilisation de cookies pour vous proposer des contenus et services adaptés à vos centres d'intérêts. En savoir plus...Fermer